JPMorgan Downgrades Lyell Immunopharma (LYEL) to Neutral 'Pending POC from Novel Cell Therapy Platform'
Tweet Send to a Friend
(Updated - August 28, 2023 4:39 AM EDT)
JPMorgan analyst Eric Joseph downgraded Lyell Immunopharma (NASDAQ: LYEL) from Overweight ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
JPMorgan analyst Eric Joseph downgraded Lyell Immunopharma (NASDAQ: LYEL) from Overweight ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
